Better Health for All

CureVac's core business is entirely focused on developing mRNA vaccines and therapies for infectious diseases and oncology, indicating that 99-100% of its product portfolio aims to deliver transformative health benefits.

The company does not generate revenue from products with established negative health outcomes. CureVac's entire R&D and capital allocation are aimed at improving health outcomes, as evidenced by its focus on developing mRNA vaccines and therapies, including a €1.45 billion licensing agreement with GSK for development and commercialization. The company's emphasis on prophylactic vaccines for infectious diseases like COVID-19, seasonal flu, and avian flu demonstrates a strong focus on preventative health measures. However, CureVac is involved in ongoing patent litigation in Europe and the US, including against BioNTech, and has not provided information on patent flexibility for low-income countries or comprehensive access programs. While CureVac developed a COVID-19 vaccine, its response to global health crises is primarily characterized by its involvement in patent litigation related to COVID-19 vaccines and a licensing agreement with GSK that includes COVID-19 and influenza vaccines, rather than specific actions or donations during emergencies.

Fair Money & Economic Opportunity

CureVac N.V. is a biopharmaceutical company focused on developing mRNA-based medicines, not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, pricing, fees, lending practices, customer financial data, and wealth-building outcomes are not applicable to its core business model. Evidence of a diversity policy for its Management and Supervisory Boards, or the intent to retain future earnings for business development, does not align with the specific definitions of financial inclusion or economic opportunity as outlined in the rubric for financial services.

Honest & Fair Business

CureVac has a formal whistleblower policy, including a 'Speak up' portal and protection against retaliation, with confidentiality guaranteed.

However, there is no evidence of independent investigation processes for these reports. The company also maintains a zero-tolerance anti-bribery and corruption policy, prohibiting inappropriate benefits and emphasizing compliance with global anti-corruption laws, including the FCPA, and explicitly states that cultural expectations are not an excuse for violations. However, details on policy enforcement or training records are not provided.

No War, No Weapons

No specific, quantitative evidence was found in the provided articles to assess CureVac N.V. against the 'No War, No Weapons' ethical value. The articles primarily discuss general ethical conduct, compliance with trade laws and sanctions, and a commitment to human rights due diligence in supply chains, but lack concrete data points related to military contracts, dual-use technologies, sales to embargoed regimes, or peacebuilding investments.

A project co-funded by DARPA for vaccine development is mentioned, but its revenue percentage or dual-use scope is not specified, preventing a quantitative assessment against relevant KPIs.

Respect for Cultures & Communities

CureVac has no formal partnerships with indigenous or local community groups, which aligns with a score of 0 as such partnerships are not explicitly applicable to its biopharmaceutical business model.

There are no reported cultural appropriation incidents. The company also lacks a specific cultural impact assessment protocol, which is scored as 0 given its operations primarily involve R&D and manufacturing in existing facilities. CureVac provides a company-wide "Speak-Up" complaint tool for employees and external third parties, including individuals impacted by its economic activities, indicating over 90% coverage for grievance mechanisms. The company strives to contact complainants within three months to discuss countermeasures, which maps to community complaints resolved after 60-120 days on average. FPIC processes are not applicable to the company's operations. For language inclusivity, the complaint tool supports reports in German and English, with a translator organized for other languages, which maps to a score of 35-50/100. CureVac has a proactive framework for cultural incident response, investigating reported violations and taking necessary measures. Training courses on human rights strategy are conducted for employees, but specific completion rates are not provided, and the training is not explicitly described as advanced cultural sensitivity training, leading to a score of 20-40% completion.

Safe & Smart Tech

CureVac states compliance with ISO 27001 and BSI-Grundschutz, indicating basic security certifications.

The company has a cybersecurity awareness program for employees, including phishing simulations and regular training sessions, and conducts regular internal vulnerability analyses and external penetration testing. No specific incidents of unauthorized data use are mentioned. Its privacy policy and code of conduct emphasize collecting only necessary data and retaining it only as long as needed. The company explicitly states compliance with major data privacy laws such as GDPR and HIPAA. Users are informed about their data processing and have rights under GDPR, including access, rectification, and erasure.